Canadian clinical-stage psychedelics company Algernon Pharmaceuticals Inc. (AGNPF) has begun screening subjects for its Phase 1 clinical study on the IV formulation of its DMT compound AP-188 in the Netherlands.

CEO Christopher J. Moreau said the company is thrilled to initiate its clinical stroke research program with this study as “preclinical data shows that DMT promotes the production of brain-derived neurotrophic factor which is an important part of the brain’s recovery process after an injury like a stroke.”

The trial, to be conducted at the Centre for Human Drug Research (CHDR) in Leiden, is expected to open enrollment shortly and dose the first participant in December 2022.

The first part of the study will use a single-escalating dose design to identify a safe and tolerable dose that will not produce psychedelic effects, while the second half will test the effects of repeated administrations of that same dose.

Read Full Story Here